CDMRP Peer Reviewed Medical Research Program: Technology/Therapeutic Development Award

The Technology/Therapeutic Development Award is a product-driven award intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, patient care, and/or quality of life, in at least one of the areas outlined below.

FY23 PRMRP Topic Areas

Autoimmune Disorders and Immunology

• Celiac Disease

• Eczema

• Food Allergies

• Guillain-Barre Syndrome

• Inflammatory Bowel Disease

• Neuroinflammatory Responses to Emerging Viral Diseases

• Proteomics

• Rheumatoid Arthritis

• Scleroderma

Cardiovascular Health

• Familial Hypercholesterolemia

• Hypercholesterolemia

• Proteomics

• Vascular Malformations

Hemorrhage Control and Blood Products

• Hemorrhage Control

• Proteomics

• Trauma

Infectious Diseases

• Hepatitis B

• Malaria

• Neuroinflammatory Responses to Emerging Viral Diseases

• Proteomics

• Tuberculosis

Internal Medicine

• Endometriosis

• Focal Segmental Glomerulosclerosis

• Interstitial Cystitis

• Lymphatic Disease

• Lymphedema

• Nephrotic Syndrome

• Pancreatitis

• Polycystic Kidney Disease

• Pressure Ulcers

• Proteomics

Neuroscience

• Eating Disorders

• Maternal Mental Health

• Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome

• Neuroactive Steroids

• Neuroinflammatory Responses to Emerging Viral Diseases

• Non-Opioid Therapy for Pain Management

• Peripheral Neuropathy

• Proteomics

• Sleep Disorders and Restriction

• Suicide Prevention

• Trauma

Orthopaedic Medicine

• Arthritis

• Orthopaedics

• Proteomics

• Trauma

Rare Diseases and Conditions

• Dystonia

• Ehlers-Danlos Syndrome

• Epidermolysis Bullosa

• Fibrous Dysplasia/McCune-Albright Syndrome

• Fragile X

• Frontotemporal Degeneration

• Hereditary Ataxia

• Hydrocephalus

• Mitochondrial Disease

• Myotonic Dystrophy

• Proteomics

• Sickle-Cell Disease

• Von Hippel-Lindau Syndrome Benign Manifestations

Respiratory Health

• Proteomics

• Pulmonary Fibrosis

• Respiratory Health

• Trauma

Level 1: significant preliminary data but not clinical translation yet

Level 2: preclinical development near-term clinical development

It is expected that 20 awards will be granted this year. 

Funding: Level 1- $2,000,000; Level 2- $4,000,000
Duration: 4 years

Research authority due date: 13.4.23

LOI (required) due date: 19.4.23
Full proposal due date: 31.5.23